Company intelligence / Profile preview
Matchpoint Therapeutics
Cambridge, Massachusetts, United Statesmatchpointtx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Matchpoint Therapeutics has not yet reported clinical results. The company’s pipeline remains preclinical/discovery-stage with a focus on developing precision covalent small molecule drugs for immune diseases using its proprietary ACE platform. No human trial data has been published as of May 2025.
- Therapeutic areas
- OtherImmunology
- Modalities
- Precision small molecules (covalent medicines)Covalent inhibitorsCovalent degraders and molecular glues (potentially)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Matchpoint Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Matchpoint Therapeutics.